Tislelizumab in Asian patients with previously treated locally advanced or metastatic urothelial carcinoma

Tislelizumab, an anti‐programmed death protein‐1 (PD‐1) monoclonal antibody, was engineered to minimize binding to the FcγR on macrophages to abrogate antibody‐dependent phagocytosis, a mechanism of T‐cell clearance and potential resistance to anti‐PD‐1 therapy. This single‐arm phase 2 trial (NCT040...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Cancer Sci
Main Authors: Ye, Dingwei, Liu, Jiyan, Zhou, Aiping, Zou, Qing, Li, Hanzhong, Fu, Cheng, Hu, Hailong, Huang, Jian, Zhu, Shaoxing, Jin, Jie, Ma, Lulin, Guo, Jianming, Xiao, Jun, Park, Se Hoon, Zhang, Dahong, Qiu, Xiusong, Bao, Yuanyuan, Zhang, Lilin, Shen, Wei, Bi, Feng
Format: Artigo
Sprog:Inglês
Udgivet: John Wiley and Sons Inc. 2020
Fag:
Clinical Research
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7780053/
https://ncbi.nlm.nih.gov/pubmed/33047430
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.14681
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker